CD8A and kidney cancer: Melanoma and kidney cancer with high expression of inhibitory receptors and low levels of CD8 T-cell infiltration may have different clinical responses to checkpoint blockade drugs compared with tumors with high CD8 T-cell infiltration, a hypothesis that awaits further testing.